ClinicalTrials.gg
CompletedNCT01576406Updated Oct 25, 2018Results posted

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

A Phase 1 interventional study of crizotinib and crizotinib in Advanced Cancer, sponsored by Pfizer. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the potential effect of hepatic impairment on the pharmacokinetics and safety of crizotinib in advanced cancer patients. Advanced cancer patients with mild, moderate or severe liver dysfunction as well as patients with normal liver function will be enrolled in this study.

02

Conditions studied

  • Advanced Cancer

Keywords

  • crizotinib
  • xalkori
  • PF-02341066
  • hepatic impairment
  • pharmacokinetics
  • advanced cancer
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid or lymphoma that is or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective. In case of hepatocellular carcinoma, the diagnosis should be based on at least one of the following:

    1. The presence of at least one lesion, measuring ≥ 2 cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or or C infection.
    2. The presence of liver lesion(s) (as defined in a.) with AFP ≥ 400 ng/mL.
    3. Tissue confirmation.
  • Biliary obstruction for whom a biliary drain or stent has been placed are eligible, provided that the drain or stent have been in place for at least 10 days prior to the first dose of crizotinib, and the liver function has stabilized as defined by 2 measurements at least 5 days apart that put the patient in the same hepatic dysfunction stratum as defined in Section 3.
  • Presence of gliomas and only if neurologically stable and treated without ongoing requirement for for at least 2 weeks.
  • Any prior systemic therapy (e.g., chemotherapy, molecularly targeted agent, immunotherapy, etc.) or major surgery must have been completed at least 30 days (or as determined by the local requirement, whichever is longer), or at least 5 half lives for drugs with half lives of 6 days or longer prior to initiation of crizotinib treatment. Any prior radiation (except palliative) or minor surgeries/procedures must have been completed at least 2 weeks prior to the initiation of crizotinib treatment. Palliative radiation (≤ 10 fractions) must have been completed 48 hours prior to the initiation of crizotinib treatment. Any acute toxicity must have recovered to Grade ≤1 (except alopecia).
  • [ECOG] performance status 0-2.
  • Adequate organ function for patients receiving crizotinib therapy as defined by the following criteria:

Bone marrow function

  • (ANC) ≥ 750/uL
  • ≥ 30,000/uL
  • ≥ 8.0 g/dL (≥ 7.0 g/dL for hematologic malignancy) Renal function
  • Creatinine ≤ 1.5 x or > 60 mL/min/1.73 m2 for patients with serum creatinine levels above institutional 1.5 x ULN

    • Male and female patients of must agree to use a highly effective method of throughout the study and for at least 28 days after the last dose of assigned treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.

Exclusion criteria

Exclusion Criteria:

  • Untreated esophageal varices observed on EGD or imaging study; however, patients with known portal hypertension and evidence of varices on EGD or imaging study who have undergone appropriate therapy as indicated within the last 6 months (if applicable) are eligible for enrollment.
  • Uncontrolled ascites that is not stable with medical management (i.e., on diuretics and salt restriction) as defined by requiring therapeutic paracentesis more than once every 4 weeks.
  • Episodes of hepatic encephalopathy within the last 4 weeks. Patients with prior episodes of hepatic encephalopathy who are clinically stable on lactulose, neomycin, and/or xifaxan therapy are allowed.
  • Prior therapy with crizotinib.
  • Spinal cord compression.
  • Carcinomatous meningitis or
  • Any of the following within the 6 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including .
  • Symptomatic congestive heart failure.
  • Ongoing cardiac dysrhythmias of Grade ≥ 2, uncontrolled atrial fibrillation of any grade, or an average of triplicate >470 msec.
  • History of extensive disseminated/bilateral or known presence of interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis.
  • Active hemolysis or evidence of biliary sepsis.
  • Pregnant females; breastfeeding females; males and females of ; males and females of childbearing potential not using highly effective or not agreeing to continue highly effective contraception for at least 28 days after last dose of product; males and females of childbearing potential not using two (2) methods of highly effective contraception or not agreeing to continue two (2) methods of highly effective contraception for at least 28 days after last dose of investigational product.
  • Use of drugs or foods that are known strong inhibitors, including but not limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice.
  • Use of drugs that are known strong CYP3A4 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort.
  • Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but not limited to dihydroergotamine, ergotamine, and pimozide.
  • Other severe acute or chronic medical (may include severe gastrointestinal conditions such as chronic diarrhea or ulcer disease) or psychiatric conditions, or laboratory abnormalities that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of the study results and, in the judgment of the investigator, would make the patient inappropriate for study entry.
  • Patients who had prior major gastrointestinal surgery removing part of gastrointestinal tract and/or gall bladder.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    A1: normal hepatic function

    Drug: crizotinib

  • Experimental
    A2: normal hepatic function

    Drug: crizotinib

  • Experimental
    B: mild hepatic impairment

    Drug: crizotinib

  • Experimental
    C: moderate hepatic impairment

    Drug: crizotinib

  • Experimental
    D: severe hepatic impairment

    Drug: crizotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1

    Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

Secondary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib: Cycle 1 Day 1

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  4. Minimum Observed Plasma Concentration (Cmin) of Crizotinib: Cycle 2 Day 1

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  5. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 2 Day 1

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  6. Plasma Accumulation Ratio (Rac) of Crizotinib

    Rac was defined as the ratio of AUCtau of Cycle 2 Day 1 to AUCtau of Cycle 1 Day 1, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing).

    Time frame: Cycle 1 Day 1 and Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  7. Apparent Oral Clearance (CL/F) of Crizotinib: Cycle 2 Day 1

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  8. Fraction of Unbound Crizotinib in Plasma: Cycle 2 Day 1

    Fraction of unbound Crizotinib concentration in plasma was defined as the ratio of unbound Crizotinib concentration to the total Crizotinib concentration.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  9. Unbound Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 2 Day 1

    Unbound area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 2 day 1.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  10. Unbound Area Under Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1

    Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  11. Unbound Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  12. Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1

    Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours postdose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  13. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1

    AUClast of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  14. Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1

    Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  15. Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1

    Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  16. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 1 Day 1

    Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  17. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 2 Day 1

    Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  18. Metabolite Ratio for Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1

    Metabolite ratio for AUCtau was defined as the ratio of AUCtau of metabolite (PF-06260182) to AUCtau of parent drug (Crizotinib), where AUCtau was the area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  19. Metabolite Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1

    Metabolite ratio for AUClast was defined as the ratio of AUClast of metabolite (PF-06260182) to AUClast of parent drug (Crizotinib), where AUClast was area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  20. Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1

    Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  21. Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1

    Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 2 Day 1.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  22. Fraction of Unbound PF-06260182 in Plasma: Cycle 2 Day 1

    Fraction of unbound PF-06260182 (a metabolite of Crizotinib) in plasma was defined as the ratio of unbound PF-06260182 concentration in plasma to the total PF-06260182 concentration.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  23. Unbound Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 2 Day 1

    Unbound AUClast of PF-06260182 (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  24. Unbound Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1

    Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. Unbound AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  25. Unbound Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1

    Unbound Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

Other outcomes

  1. Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  2. Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  3. Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1

    AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  4. Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1

    Unbound AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure, where AUCdaily was area under the plasma concentration time curve as daily exposure post-dose.

    Time frame: Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

  5. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 4 years that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: From initiation of treatment up to follow-up period (up to 4 years)

  6. Number of Participants With Treatment-Emergent Adverse Events, by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events \[CTCAE\] Version 4.0. Grade 1 =mild; Grade 2 =moderate; Grade 3 =severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4 =life-threatening or disabling, urgent intervention indicated; Grade 5 =death. Treatment-emergent events were events between first dose of study drug and up to 4 years that were absent before treatment that worsened relative to pretreatment state. If the same participant in a given treatment had more than 1 adverse event, only the maximum CTCAE was reported.

    Time frame: From initiation of treatment up to follow-up period (up to 4 years)

  7. Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non-serious adverse events.

    Time frame: From initiation of treatment up to follow-up period (up to 4 years)

  8. Number of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Hematological Test Abnormalities

    Anemia(grade\[g\]1:Less than\[\<\] Lower limit of normal\[LLN\] to 10gram per\[/\] deciliter\[g/dL\],g2:\<10 to 8g/dL,g3:\<8g/dL,g4:lifethreatening);platelet (g1:\<LLN to 75\*10\^3/millimeter\[mm\]\^3,g2:\<75\*10\^3/mm\^3 to 50\*10\^3/mm\^3,g3:\<50\*10\^3/mm\^3 to 25\*10\^3/mm\^3,g4:\<25\*10\^3/mm\^3);lymphopenia(g1:\<LLN to 8\*10\^2/mm\^3,g2:\<8\*10\^2 to 5\*10\^2/mm\^3,g3:\<5\*10\^2 to 2\*10\^2/mm\^3,g4:\<2\*10\^2/mm\^3);neutrophil (Absolute)(g1:\<LLN to 15\*10\^2/mm\^3,g2:\<15\*10\^2 to 10\*10\^2/mm\^3,g3:\<10\*10\^2 to 5\*10\^2/mm\^3,g4:\<5\*10\^2/mm\^3);white blood cell count(g1:\<LLN to 3\*10\^3/mm\^3,g2:\<3\*10\^3 to 2\*10\^3/mm\^3,g3:\<2\*10\^3 to 1\*10\^3/mm\^3,g4:\<1\*10\^3/mm\^3);hemoglobin(g1:increase in hemoglobin level\>0 to 2 g/dL above ULN or above baseline if baseline is above ULN,g2:increase in hemoglobin level\>2 to 4g/dL above ULN or above baseline if baseline is above ULN,g3:increase in hemoglobin level\>4 g/dL above ULN or above baseline if baseline is above ULN). Only categories with atleast 1 participant with abnormality are reported in this outcome measure.

    Time frame: Baseline up to end of treatment (up to 728 days)

  9. Number of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Chemistry Test Abnormalities

    ALT/AST(grade\[g\]1:\>ULN-3\*ULN,g2:\>3-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);AP(g1:\>ULN-2.5\*ULN,g2:\>2.5-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);CR(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-6\*ULN,g4:\>6\*ULN);hyperglycemia(g1:\>ULN-160mg/dL,g2:\>160-250mg/dL,g3:\>250-500mg/dL,g4:\>500mg/dL);bilirubin(total)(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-10\*ULN,g4:\>10\*ULN);hypoglycemia(g1:\<LLN-55mg/dL,g2:\<55-40mg/dL,g3:\<40-30mg/dL,g4:\<30mg/dL);hyperkalemia(g1:\>ULN-5.5mmol/L,g2:\>5.5-6mmol/L,g3:\>6-7mmol/L,g4:\>7mmol/L);hypokalemia(g1:\<LLN-3mmol/L,g2:\<LLN-3mmol/L,g3:\<3-2.5mmol/L,g4:\<2.5mmol/L);hypermagnesemia(g1:\>ULN-3mg/dL,g3:\>3-8mg/dL,g4:\>8mg/dL);hypocalcemia(g1:\<LLN-8mg/dL,g2:\<8-7mg/dL,g3:\<7-6mg/dL,g4:\<6mg/dL);hypomagnesemia(g1:\<LLN-1.2mg/dL,g2:\<1.2-0.9mg/dL,g3:\<0.9-0.7mg/dL,g4:\<0.7mg/dL);hyponatremia(g1:\<LLN-130mmol/L,g3:\<130-120mmol/L,g4:\<120mmol/L);hypoalbuminemia(g1:\<LLN-3g/dL,g2:\<3-2g/dL,g3:\<2g/dL,g4:lifethreatening);hypophosphatemia(g1:\<LLN-2.5mg/dL,g2:\<2.5-2mg/dL,g3:\<2-1mg/dL,g4:\<1mg/dL).Participant\>=1abnormality given.

    Time frame: Baseline up to end of treatment (up to 728 days)

  10. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Criteria for abnormal value of ECG parameters: maximum increase from baseline (IFB) in QT interval using Fridericia's correction (QTcF)/QT interval using Bazett's correction (QTcB) range from less than (\<)30 millisecond (msec), 30 to \<60, greater than or equal to (\>=)60 msec; maximum post-dose QTcF/QTcB ranges from \<450 msec, 450 to \<480 msec, 480 to \<500, and \>=500 msec; PR interval: \>=50 percent (%) increase when baseline \<200 msec; or increase \>=25% when baseline less than or equal to (\<=)200 msec; QRS interval: \>=50% increase when baseline \<100 msec; \>=25% increase when baseline \>=100 msec. Only categories which included atleast 1 participant with abnormality are reported in this outcome measure.

    Time frame: Baseline up to end of treatment (up to 728 days)

  11. Number of Participants With Abnormal Fundoscopy Examination Findings

    Fundoscopy examination included an examination of the vitreous body, retina macula, retina non-macula, optic nerve head, optic disc notching and fundus using the category of the examination status (normal, mild, moderate, or severe). In this outcome measure, number of participants with abnormal fundoscopy values identified by investigator were reported.

    Time frame: Baseline up to end of treatment (up to 728 days)

  12. Objective Response Rate (ORR)

    ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version 1.1. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confirmed responses were those who persisted on repeat imaging study at least 4 weeks after the initial documentation of response.

    Time frame: Baseline, every 8 weeks until disease progression or unacceptable toxicity up to end of treatment (up to 728 days)

  13. Duration of Response (DR)

    DR was defined as the time from date of first documentation of CR or PR to first documentation of objective tumor progression or death due to any cause, whichever occurred first. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Objective tumor progression as per RECIST version 1.1 was defined as \>=20% increase in sum of diameters of target lesions taking as a reference smallest sum of diameters recorded since treatment started, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier method.

    Time frame: Baseline, every 8 weeks until disease progression or unacceptable toxicity up to end of treatment (up to 728 days)

07

Results

Posted Oct 25, 2018

Participant flow

Participant flow — Overall Study
MilestoneNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Started111520101616
Completed574184
Not completed68169812
Withdrew: Lost to follow-up120000
Withdrew: Death348579
Withdrew: Non-clinical trial supply of crizotinib001100
Withdrew: Withdrawal the consent225113
Withdrew: Other002200

Outcome measures

PrimaryArea Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1

Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1
nanogram*hour per milliliter (ng*hr/mL)Normal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 13552 ± 482712 ± 663238 ± 732305 ± 834057 ± 584596 ± 63
PrimaryMaximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1
Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1
nanogram per milliliter (ng/mL)Normal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1375.1 ± 50283.9 ± 65342.1 ± 68152.9 ± 58408.3 ± 56272.4 ± 29
Statistical analysis
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily · Geometric mean ratio: 91.20 · 90% CI 57.47 to 144.72
  • Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily vs Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily · Geometric mean ratio: 143.82 · 90% CI 89.11 to 232.12
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily · Geometric mean ratio: 108.87 · 90% CI 70.13 to 168.99
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Severe Hepatic Impairment Crizotinib 250 mg Once Daily · Geometric mean ratio: 72.63 · 90% CI 49.07 to 107.50
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1
Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 1 Day 1732.3 ± 84520.8 ± 49557.5 ± 78610.4 ± 128684.9 ± 89856.7 ± 57
SecondaryMaximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1
Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1
ng/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 1 Day 1101.9 ± 9284.52 ± 67102.3 ± 6657.74 ± 11299.59 ± 8890.69 ± 63
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib: Cycle 1 Day 1
Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib: Cycle 1 Day 1
hourNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib: Cycle 1 Day 14.00 (1.00 to 6.00)4.00 (1.00 to 6.00)4.00 (1.92 to 10.9)2.02 (1.00 to 4.05)4.00 (1.00 to 8.00)3.00 (1.00 to 6.00)
SecondaryMinimum Observed Plasma Concentration (Cmin) of Crizotinib: Cycle 2 Day 1
Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Minimum Observed Plasma Concentration (Cmin) of Crizotinib: Cycle 2 Day 1
ng/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Minimum Observed Plasma Concentration (Cmin) of Crizotinib: Cycle 2 Day 1238.6 ± 52170.9 ± 75179.1 ± 10147.44 ± 376287.0 ± 58135.5 ± 102
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 2 Day 1
Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

No measurements were reported for this outcome.

SecondaryPlasma Accumulation Ratio (Rac) of Crizotinib

Rac was defined as the ratio of AUCtau of Cycle 2 Day 1 to AUCtau of Cycle 1 Day 1, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing).

Time frame:
Cycle 1 Day 1 and Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

No measurements were reported for this outcome.

SecondaryApparent Oral Clearance (CL/F) of Crizotinib: Cycle 2 Day 1

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent oral clearance was obtained by dividing study drug dose with AUCtau, where AUCtau was area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · Liter/hour
Apparent Oral Clearance (CL/F) of Crizotinib: Cycle 2 Day 1
Liter/hourNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Apparent Oral Clearance (CL/F) of Crizotinib: Cycle 2 Day 170.39 ± 4873.79 ± 6677.21 ± 73108.5 ± 8349.26 ± 5854.36 ± 63
SecondaryFraction of Unbound Crizotinib in Plasma: Cycle 2 Day 1

Fraction of unbound Crizotinib concentration in plasma was defined as the ratio of unbound Crizotinib concentration to the total Crizotinib concentration.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ratio
Fraction of Unbound Crizotinib in Plasma: Cycle 2 Day 1
ratioNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Fraction of Unbound Crizotinib in Plasma: Cycle 2 Day 10.03624 ± 260.03066 ± 270.04315 ± 310.05406 ± 200.04152 ± 340.03523 ± 46
SecondaryUnbound Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of Crizotinib: Cycle 2 Day 1

Unbound area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 2 day 1.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

No measurements were reported for this outcome.

SecondaryUnbound Area Under Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1

Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Unbound Area Under Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib: Cycle 2 Day 1128.7 ± 3883.08 ± 73139.7 ± 94124.6 ± 85168.6 ± 59161.9 ± 48
SecondaryUnbound Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1
Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Unbound Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 1
ng/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Unbound Maximum Observed Plasma Concentration (Cmax) of Crizotinib: Cycle 2 Day 113.59 ± 418.703 ± 7414.77 ± 938.271 ± 6216.96 ± 569.608 ± 34
SecondaryArea Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1

Area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours postdose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 11087 ± 43717.4 ± 81480.3 ± 168200.0 ± 48391.8 ± 118434.0 ± 96
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1

AUClast of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1272.4 ± 80166.5 ± 3190.71 ± 15364.90 ± 10353.36 ± 13959.61 ± 81
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1

Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1
ng/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 135.48 ± 8624.12 ± 3313.54 ± 1534.869 ± 956.995 ± 1524.088 ± 88
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1

Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1
ng/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1108.5 ± 4373.47 ± 7650.34 ± 16412.43 ± 5539.32 ± 12025.15 ± 110
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 1 Day 1

Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 1 Day 1
hourNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 1 Day 16.04 (4.00 to 8.00)4.00 (2.00 to 8.00)4.00 (4.00 to 10.9)6.08 (5.93 to 8.00)8.00 (4.00 to 12.00)7.00 (4.00 to 8.00)
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 2 Day 1

Tmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 2 Day 1
hourNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06260182: Cycle 2 Day 16.00 (0.983 to 10.0)4.03 (1.00 to 7.45)4.00 (0 to 10.8)6.00 (4.05 to 7.30)0 (0 to 6.00)6.69 (0 to 8.00)
SecondaryMetabolite Ratio for Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1

Metabolite ratio for AUCtau was defined as the ratio of AUCtau of metabolite (PF-06260182) to AUCtau of parent drug (Crizotinib), where AUCtau was the area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite Ratio for Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1
ratioNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Metabolite Ratio for Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 10.2968 ± 170.2569 ± 310.1439 ± 740.08402 ± 650.09360 ± 470.09162 ± 47
SecondaryMetabolite Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1

Metabolite ratio for AUClast was defined as the ratio of AUClast of metabolite (PF-06260182) to AUClast of parent drug (Crizotinib), where AUClast was area under the plasma concentration-time curve from time zero to the last quantifiable plasma concentration post-dose of Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 1
ratioNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Metabolite Ratio for Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 1 Day 10.3608 ± 180.3104 ± 300.1577 ± 600.1032 ± 720.07566 ± 420.06753 ± 21
SecondaryMetabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1

Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 1
ratioNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 1 Day 10.3378 ± 250.2769 ± 410.1284 ± 700.08178 ± 660.06809 ± 470.04373 ± 42
SecondaryMetabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1

Metabolite ratio for Cmax was defined as the ratio of Cmax of metabolite (PF-06260182) to Cmax of parent drug (Crizotinib), where Cmax was maximum observed plasma concentration post-dose of Cycle 2 Day 1.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ratio
Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1
ratioNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Metabolite Ratio for Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 10.2804 ± 190.2511 ± 310.1428 ± 730.07881 ± 580.09337 ± 490.08954 ± 90
SecondaryFraction of Unbound PF-06260182 in Plasma: Cycle 2 Day 1

Fraction of unbound PF-06260182 (a metabolite of Crizotinib) in plasma was defined as the ratio of unbound PF-06260182 concentration in plasma to the total PF-06260182 concentration.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ratio
Fraction of Unbound PF-06260182 in Plasma: Cycle 2 Day 1
ratioNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Fraction of Unbound PF-06260182 in Plasma: Cycle 2 Day 10.03797 ± 110.03822 ± 160.04857 ± 160.05788 ± 220.05031 ± 100.05177 ± 13
SecondaryUnbound Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Plasma Concentration (AUClast) of PF-06260182: Cycle 2 Day 1

Unbound AUClast of PF-06260182 (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose

No measurements were reported for this outcome.

SecondaryUnbound Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1

Unbound area under the plasma concentration-time curve from time zero to the quantifiable concentration at the end of dosing interval (tau hours post-dose, where tau was 12 hours for twice daily dosing and 24 hours for once daily dosing) of Cycle 2 Day 1. Unbound AUCtau of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Unbound Area Under Plasma Concentration Time Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06260182: Cycle 2 Day 141.26 ± 3627.40 ± 9923.35 ± 18111.56 ± 4919.71 ± 11922.49 ± 79
SecondaryUnbound Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1

Unbound Cmax of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng/mL
Unbound Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 1
ng/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Unbound Maximum Observed Plasma Concentration (Cmax) of PF-06260182: Cycle 2 Day 14.119 ± 362.806 ± 942.445 ± 1780.7194 ± 501.977 ± 1221.301 ± 93
Other pre-specifiedArea Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1
Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 17107 ± 485422 ± 666476 ± 732305 ± 838108 ± 584596 ± 63
Statistical analysis
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily · Percentage of ratio of geometric mean: 91.12 · 90% CI 56.56 to 146.79
  • Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily vs Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily · Percentage of ratio of geometric mean: 149.54 · 90% CI 91.85 to 243.46
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily · Percentage of ratio of geometric mean: 114.08 · 90% CI 73.57 to 176.89
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Severe Hepatic Impairment Crizotinib 250 mg Once Daily · Percentage of ratio of geometric mean: 64.67 · 90% CI 39.50 to 105.89
Other pre-specifiedUnbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1
Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of Crizotinib: Cycle 2 Day 1257.7 ± 38166.1 ± 73279.4 ± 95124.6 ± 85337.0 ± 59161.9 ± 48
Statistical analysis
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily · Percentage of ratio of geometric mean: 108.43 · 90% CI 63.47 to 185.26
  • Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily vs Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily · Percentage of ratio of geometric mean: 202.89 · 90% CI 120.96 to 340.30
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily · Percentage of ratio of geometric mean: 130.78 · 90% CI 86.61 to 197.47
  • Normal Hepatic Function: Crizotinib 250 mg Twice Daily vs Severe Hepatic Impairment Crizotinib 250 mg Once Daily · Percentage of ratio of geometric mean: 62.82 · 90% CI 42.54 to 92.78
Other pre-specifiedArea Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1

AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 12173 ± 431435 ± 81961.2 ± 168200.0 ± 48784.0 ± 117434.0 ± 96
Other pre-specifiedUnbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1

Unbound AUCdaily of PF-06260182, (a metabolite of Crizotinib) is reported in this outcome measure, where AUCdaily was area under the plasma concentration time curve as daily exposure post-dose.

Time frame:
Cycle 2 Day 1- Twice daily dosing: pre-dose and 1, 2, 4, 6, 8, 12 hours post-dose; Once daily dosing: pre-dose and 1, 2, 4, 6, 8, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 1
ng*hr/mLNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Unbound Area Under the Plasma Concentration Time Curve as Daily Exposure (AUCdaily) of PF-06260182: Cycle 2 Day 182.56 ± 3654.85 ± 9946.66 ± 18111.56 ± 4939.41 ± 11922.49 ± 79
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 4 years that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
From initiation of treatment up to follow-up period (up to 4 years)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
AEs11152091616
SAEs781361414
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events, by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events \[CTCAE\] Version 4.0. Grade 1 =mild; Grade 2 =moderate; Grade 3 =severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated; Grade 4 =life-threatening or disabling, urgent intervention indicated; Grade 5 =death. Treatment-emergent events were events between first dose of study drug and up to 4 years that were absent before treatment that worsened relative to pretreatment state. If the same participant in a given treatment had more than 1 adverse event, only the maximum CTCAE was reported.

Time frame:
From initiation of treatment up to follow-up period (up to 4 years)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events, by National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE) (Version 4.0) Grade
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Grade 1 AEs122000
Grade 2 AEs265101
Grade 3 AEs635298
Grade 4 AEs012120
Grade 5 AEs236557
Other pre-specifiedNumber of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both serious and non-serious adverse events.

Time frame:
From initiation of treatment up to follow-up period (up to 4 years)
Reported as:
Number · participants
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
AE9141561111
SAE030000
Other pre-specifiedNumber of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Hematological Test Abnormalities

Anemia(grade\[g\]1:Less than\[\<\] Lower limit of normal\[LLN\] to 10gram per\[/\] deciliter\[g/dL\],g2:\<10 to 8g/dL,g3:\<8g/dL,g4:lifethreatening);platelet (g1:\<LLN to 75\*10\^3/millimeter\[mm\]\^3,g2:\<75\*10\^3/mm\^3 to 50\*10\^3/mm\^3,g3:\<50\*10\^3/mm\^3 to 25\*10\^3/mm\^3,g4:\<25\*10\^3/mm\^3);lymphopenia(g1:\<LLN to 8\*10\^2/mm\^3,g2:\<8\*10\^2 to 5\*10\^2/mm\^3,g3:\<5\*10\^2 to 2\*10\^2/mm\^3,g4:\<2\*10\^2/mm\^3);neutrophil (Absolute)(g1:\<LLN to 15\*10\^2/mm\^3,g2:\<15\*10\^2 to 10\*10\^2/mm\^3,g3:\<10\*10\^2 to 5\*10\^2/mm\^3,g4:\<5\*10\^2/mm\^3);white blood cell count(g1:\<LLN to 3\*10\^3/mm\^3,g2:\<3\*10\^3 to 2\*10\^3/mm\^3,g3:\<2\*10\^3 to 1\*10\^3/mm\^3,g4:\<1\*10\^3/mm\^3);hemoglobin(g1:increase in hemoglobin level\>0 to 2 g/dL above ULN or above baseline if baseline is above ULN,g2:increase in hemoglobin level\>2 to 4g/dL above ULN or above baseline if baseline is above ULN,g3:increase in hemoglobin level\>4 g/dL above ULN or above baseline if baseline is above ULN). Only categories with atleast 1 participant with abnormality are reported in this outcome measure.

Time frame:
Baseline up to end of treatment (up to 728 days)
Reported as:
Number · participants
Number of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Hematological Test Abnormalities
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Anemia: Grade 1479978
Anemia: Grade 2474155
Anemia: Grade 3113011
Hemoglobin Increased: Grade 1001000
Lymphopenia: Grade 1225201
Lymphopenia: Grade 2374697
Lymphopenia: Grade 3113224
Lymphopenia: Grade 4000020
Neutrophils (Absolute): Grade 1001212
Neutrophils (Absolute): Grade 2312030
Neutrophils (Absolute): Grade 3001013
Platelets: Grade 1024283
Platelets: Grade 2001022
Platelets: Grade 3002325
White Blood Cells: Grade 1234221
White Blood Cells: Grade 2113233
White Blood Cells: Grade 3000013
Other pre-specifiedNumber of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Chemistry Test Abnormalities

ALT/AST(grade\[g\]1:\>ULN-3\*ULN,g2:\>3-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);AP(g1:\>ULN-2.5\*ULN,g2:\>2.5-5\*ULN,g3:\>5-20\*ULN,g4:\>20\*ULN);CR(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-6\*ULN,g4:\>6\*ULN);hyperglycemia(g1:\>ULN-160mg/dL,g2:\>160-250mg/dL,g3:\>250-500mg/dL,g4:\>500mg/dL);bilirubin(total)(g1:\>ULN-1.5\*ULN,g2:\>1.5-3\*ULN,g3:\>3-10\*ULN,g4:\>10\*ULN);hypoglycemia(g1:\<LLN-55mg/dL,g2:\<55-40mg/dL,g3:\<40-30mg/dL,g4:\<30mg/dL);hyperkalemia(g1:\>ULN-5.5mmol/L,g2:\>5.5-6mmol/L,g3:\>6-7mmol/L,g4:\>7mmol/L);hypokalemia(g1:\<LLN-3mmol/L,g2:\<LLN-3mmol/L,g3:\<3-2.5mmol/L,g4:\<2.5mmol/L);hypermagnesemia(g1:\>ULN-3mg/dL,g3:\>3-8mg/dL,g4:\>8mg/dL);hypocalcemia(g1:\<LLN-8mg/dL,g2:\<8-7mg/dL,g3:\<7-6mg/dL,g4:\<6mg/dL);hypomagnesemia(g1:\<LLN-1.2mg/dL,g2:\<1.2-0.9mg/dL,g3:\<0.9-0.7mg/dL,g4:\<0.7mg/dL);hyponatremia(g1:\<LLN-130mmol/L,g3:\<130-120mmol/L,g4:\<120mmol/L);hypoalbuminemia(g1:\<LLN-3g/dL,g2:\<3-2g/dL,g3:\<2g/dL,g4:lifethreatening);hypophosphatemia(g1:\<LLN-2.5mg/dL,g2:\<2.5-2mg/dL,g3:\<2-1mg/dL,g4:\<1mg/dL).Participant\>=1abnormality given.

Time frame:
Baseline up to end of treatment (up to 728 days)
Reported as:
Number · participants
Number of Participants With Laboratory Test Abnormalities: NCI CTCAE (Version 4.0) Grade 1 to 4 Chemistry Test Abnormalities
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Alanine aminotransferase (ALT): Grade 183126129
ALT: Grade 2005235
ALT: Grade 3000110
Alkaline phosphatase(AP): Grade 1478475
Alkaline phosphatase: Grade 2215344
Alkaline phosphatase: Grade 3013346
AST:Grade 1678544
AST: Grade 2107073
AST: Grade 3013557
AST: Grade 4000002
Bilirubin (total): Grade 1102000
Bilirubin (total): Grade 2103170
Bilirubin (total): Grade 30025810
Bilirubin (total): Grade 4002316
Creatinine (CR): Grade 191186610
CR: Grade 2247385
CR: Grade 3001011
Hyperglycemia: Grade 15810858
Hyperglycemia: Grade 2125042
Hyperglycemia: Grade 3011004
Hyperkalemia: Grade 1214231
Hyperkalemia: Grade 2001000
Hyperkalemia: Grade 3001010
Hypermagnesemia: Grade 1114023
Hypoalbuminemia: Grade 1542100
Hypoalbuminemia: Grade 251098148
Hypoalbuminemia: Grade 3003127
Hypocalcemia: Grade 15115347
Hypocalcemia: Grade 2319499
Hypoglycemia: Grade 1002022
Hypokalemia: Grade 1415054
Hypokalemia: Grade 3000100
Hypomagnesemia: Grade 1025346
Hyponatremia: Grade 1554578
Hyponatremia: Grade 3147577
Hypophosphatemia: Grade 1031001
Hypophosphatemia: Grade 2123333
Hypophosphatemia: Grade 3201131
Other pre-specifiedNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Criteria for abnormal value of ECG parameters: maximum increase from baseline (IFB) in QT interval using Fridericia's correction (QTcF)/QT interval using Bazett's correction (QTcB) range from less than (\<)30 millisecond (msec), 30 to \<60, greater than or equal to (\>=)60 msec; maximum post-dose QTcF/QTcB ranges from \<450 msec, 450 to \<480 msec, 480 to \<500, and \>=500 msec; PR interval: \>=50 percent (%) increase when baseline \<200 msec; or increase \>=25% when baseline less than or equal to (\<=)200 msec; QRS interval: \>=50% increase when baseline \<100 msec; \>=25% increase when baseline \>=100 msec. Only categories which included atleast 1 participant with abnormality are reported in this outcome measure.

Time frame:
Baseline up to end of treatment (up to 728 days)
Reported as:
Number · participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Maximum Post-dose QTCF Interval: <450 msec913138116
Maximum Post-dose QTCF Interval: 450 to <480 msec126159
Maximum Post-dose QTCF Interval: 480 to <500 msec100101
Maximum Post-dose QTCF Interval: >=500 msec001000
Maximum Post-dose QTCB Interval: <450 msec1013127115
Maximum Post-dose QTCB Interval: 450 to <480 msec027258
Maximum Post-dose QTCB Interval: 480 to <500 msec100101
Maximum Post-dose QTCB Interval: >=500 msec001002
Maximum QTCF Interval IFB: <30 msec71211778
Maximum QTCF Interval IFB: 30 to 60 msec211041
Maximum QTCF IFB: >=60 msec000101
Maximum QTCB Interval IFB: <30 msec7108577
Maximum QTCB Interval IFB: 30 to 60 msec010111
Maximum QTCB Interval IFB: >=60 msec000101
Maximum PR Interval IFB: >=50%010000
Maximum PR Interval IFB, Other Than: >=25 or 50%101419101516
Maximum QRS Interval IFB, Other Than: >=25 or 50%111520101616
Other pre-specifiedNumber of Participants With Abnormal Fundoscopy Examination Findings

Fundoscopy examination included an examination of the vitreous body, retina macula, retina non-macula, optic nerve head, optic disc notching and fundus using the category of the examination status (normal, mild, moderate, or severe). In this outcome measure, number of participants with abnormal fundoscopy values identified by investigator were reported.

Time frame:
Baseline up to end of treatment (up to 728 days)
Reported as:
Number · participants
Number of Participants With Abnormal Fundoscopy Examination Findings
participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Right Eye, Retina Macula: Mild Abnormality001000
Right Eye, Retina Non-Macula: Mild Abnormality100000
Right Eye, Optic Disc Notching: Mild Abnormality110000
Right Eye, Fundus: Mild Abnormality001000
Right Eye, Vitreous Body: Mild Abnormality000100
Left Eye, Retina Non-Macula: Mild Abnormality100010
Left Eye, Vitreous Body: Mild Abnormality100100
Left Eye, Fundus: Mild Abnormality001000
Left Eye, Retina Macula: Mild Abnormality001000
Left Eye, Optic Disc Notching: Mild Abnormality100000
Other pre-specifiedObjective Response Rate (ORR)

ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST) version 1.1. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Confirmed responses were those who persisted on repeat imaging study at least 4 weeks after the initial documentation of response.

Time frame:
Baseline, every 8 weeks until disease progression or unacceptable toxicity up to end of treatment (up to 728 days)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Objective Response Rate (ORR)9.1 (0.2 to 41.3)0 (0.0 to 21.8)5.0 (0.1 to 24.9)0 (0.0 to 30.8)6.3 (0.2 to 30.2)0 (0.0 to 20.6)
Other pre-specifiedDuration of Response (DR)

DR was defined as the time from date of first documentation of CR or PR to first documentation of objective tumor progression or death due to any cause, whichever occurred first. In case of target lesions CR was defined as the disappearance of all target lesions and in case nodal disease included in the sum of target lesions. The nodes decreased to normal size (\<10 mm). In case of non-target lesions disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Objective tumor progression as per RECIST version 1.1 was defined as \>=20% increase in sum of diameters of target lesions taking as a reference smallest sum of diameters recorded since treatment started, or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier method.

Time frame:
Baseline, every 8 weeks until disease progression or unacceptable toxicity up to end of treatment (up to 728 days)
Reported as:
Median · week
Duration of Response (DR)
weekNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Duration of Response (DR)NA (NA to NA)—17.4 (NA to NA)—NA (NA to NA)—

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Hepatic Function: Crizotinib 250 mg Twice Daily3/11 (27.3%)7/11 (63.6%)11/11 (100%)
Normal Hepatic Function: Crizotinib 200/250 mg Twice Daily4/15 (26.7%)8/15 (53.3%)15/15 (100%)
Mild Hepatic Impairment: Crizotinib 250 mg Twice Daily8/20 (40%)13/20 (65%)20/20 (100%)
Moderate Hepatic Impairment Crizotinib 200 mg Twice Daily5/10 (50%)6/10 (60%)9/10 (90%)
Moderate Hepatic Impairment: Crizotinib 250 mg Once Daily7/16 (43.8%)14/16 (87.5%)16/16 (100%)
Severe Hepatic Impairment Crizotinib 250 mg Once Daily9/16 (56.3%)14/16 (87.5%)16/16 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
Disease progressionGeneral disorders2/112/154/205/104/166/16
AscitesGastrointestinal disorders0/110/150/202/102/164/16
Hepatic encephalopathyNervous system disorders0/110/151/202/102/162/16
PneumonitisRespiratory, thoracic and mediastinal disorders0/112/150/200/100/160/16
Atrial fibrillationCardiac disorders0/110/150/200/102/160/16
Hepatic failureHepatobiliary disorders0/110/150/200/102/160/16
PneumoniaInfections and infestations0/111/151/200/101/162/16
Confusional statePsychiatric disorders0/110/150/200/102/160/16
Pleural effusionRespiratory, thoracic and mediastinal disorders0/110/150/201/102/160/16
Small intestinal obstructionGastrointestinal disorders0/110/150/201/101/160/16
Most frequent other events
Showing 10 of 153
Most frequent other events
EventNormal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailySevere Hepatic Impairment Crizotinib 250 mg Once Daily
DiarrhoeaGastrointestinal disorders7/114/155/201/101/161/16
NauseaGastrointestinal disorders7/118/1511/202/107/166/16
HyponatraemiaMetabolism and nutrition disorders0/116/155/206/104/166/16
VomitingGastrointestinal disorders4/118/156/202/109/163/16
ConstipationGastrointestinal disorders6/112/154/201/104/162/16
FatigueGeneral disorders4/116/154/205/108/167/16
HyperbilirubinaemiaHepatobiliary disorders0/110/154/202/108/160/16
Blood bilirubin increasedInvestigations0/110/152/205/101/161/16
Blood creatinine increasedInvestigations5/114/155/204/103/163/16
HypophosphataemiaMetabolism and nutrition disorders1/112/151/204/102/162/16

Baseline characteristics

Safety analysis population included all enrolled participants who received at least 1 dose of Crizotinib on Cycle 1, Day 1.

Age, Continuous
Age, Continuous(years)Normal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once DailyTotal
Mean57.7 ± 15.6462.9 ± 10.3561.2 ± 10.1459.2 ± 8.8560.3 ± 7.8759.0 ± 6.0460.3 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Normal Hepatic Function: Crizotinib 250 mg Twice DailyNormal Hepatic Function: Crizotinib 200/250 mg Twice DailyMild Hepatic Impairment: Crizotinib 250 mg Twice DailyModerate Hepatic Impairment: Crizotinib 250 mg Once DailyModerate Hepatic Impairment Crizotinib 200 mg Twice DailySevere Hepatic Impairment Crizotinib 250 mg Once DailyTotal
Female46726631
Male79138101057
08

Study locations

20 sites
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • LAC&USC Medical Center
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Anschutz Cancer Pavilion, Room 2224, c/o Melinda Friesleben, Pharm D
    Aurora, Colorado 80045, United States
  • University of Colorado Denver - Clinical Translational Research Center
    Aurora, Colorado 80045, United States
  • University of Colorado Denver, Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Denver, Anschutz Inpatient Pavillion
    Aurora, Colorado 80045, United States
  • Emory University Hospital Midtown Laboratory
    Atlanta, Georgia 30308, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Investigational Drug Service: The Emory Clinic Bldg A
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • University Hospital East
    Columbus, Ohio 43205, United States
  • Investigational Drug Services
    Columbus, Ohio 43210, United States
  • James Cancer Hospital
    Columbus, Ohio 43210, United States
  • The Ohio State University, Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Martha Morehouse Medical Plaza
    Columbus, Ohio 43221, United States
  • Cancer Therapy & Research Center at UTHSCSA
    San Antonio, Texas 78229, United States
  • Medical Arts and Research Center-MARC
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF. Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 2018 Apr;81(4):659-670. doi: 10.1007/s00280-018-3517-8. Epub 2018 Feb 21. PubMed 29468455 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Jun 2016, 47 months.

Results were first posted in Oct 2018, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2012
First posted
Apr 12, 2012
StartActual
Jul 2012
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results first posted
Oct 25, 2018
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01576406
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 12, 2012
Start date
Jul 2012
Primary completion
Jun 2016
Completion
Jun 2016
Results posted
Oct 25, 2018
Last update
Oct 25, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crizotinib

Start the discussion